A traditional Chinese medicine composition for treating cardiovascular and cerebrovascular disease, the active ingredients thereof being composed of: 1) an ethanol extract of 6-12 parts of Ligusticum wallichii and 5-10 parts of Curcumae Radix, and 2) an aqueous extract of extract residue of the described Ligusticum wallichii and Curcumae Radix and 5-10 parts of Radix Cyathulae; the traditional Chinese medicine composition may further comprise an aqueous extract of 5-10 parts of Allium macrostemon and 6-12 parts of Eucommia ulmoides. The traditional Chinese medicine composition relates to medicine made from plant compounds, and has significant medicinal effects on myocardial contraction disorder and myocardial dilation disorder, platelet aggregation thrombosis and myocardial ischemia, myocardial hypoxia, myocardial fatigue, and so on, being particularly suitable for treating coronary heart disease and chronic or acute heart failure.

The present invention relates to a method of treating meningioma including administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture comprising Coptis chinensis, Phellodendron amurense, Glycyrrhiza uralensis, Atractylodes lancea, Artemisia carvifolia, Anemarrhena asphodeloides, and Cortex Lycii.

The present invention relates to a method of treating meningioma including administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture comprising Coptis chinensis, Phellodendron amurense, Glycyrrhiza uralensis, Atractylodes lancea, Artemisia carvifolia, Anemarrhena asphodeloides, and Cortex Lycii.

An herbal tea product is provided to provide relief from lung and breathing conditions such as asthma. The herbal tea product may include oregano, peppermint, OSHA root, lungwort, eucalyptus, plantain leaf, chaparral, elecampane, lobelia, sage, licorice root, and thyme. The herbal ingredients may be included in equal amounts, such as 5 ounces. The OSHA root, elecampane, and/or licorice root may be crushed. Methods of making and using the herbal tea product are also disclosed. The herbal tea product may be placed into tea bags, and prepared for human consumption by placing the tea bag with herbal tea product in hot water that has been brought to a boil. The herbal tea product may be consumed in appropriate amounts, such as 16 ounces, twice a day for two weeks, and then once a day thereafter.

An herbal tea product is provided to provide relief from lung and breathing conditions such as asthma. The herbal tea product may include oregano, peppermint, OSHA root, lungwort, eucalyptus, plantain leaf, chaparral, elecampane, lobelia, sage, licorice root, and thyme. The herbal ingredients may be included in equal amounts, such as 5 ounces. The OSHA root, elecampane, and/or licorice root may be crushed. Methods of making and using the herbal tea product are also disclosed. The herbal tea product may be placed into tea bags, and prepared for human consumption by placing the tea bag with herbal tea product in hot water that has been brought to a boil. The herbal tea product may be consumed in appropriate amounts, such as 16 ounces, twice a day for two weeks, and then once a day thereafter.

An herbal tea product is provided to provide relief from lung and breathing conditions such as asthma. The herbal tea product may include oregano, peppermint, OSHA root, lungwort, eucalyptus, plantain leaf, chaparral, elecampane, lobelia, sage, licorice root, and thyme. The herbal ingredients may be included in equal amounts, such as 5 ounces. The OSHA root, elecampane, and/or licorice root may be crushed. Methods of making and using the herbal tea product are also disclosed. The herbal tea product may be placed into tea bags, and prepared for human consumption by placing the tea bag with herbal tea product in hot water that has been brought to a boil. The herbal tea product may be consumed in appropriate amounts, such as 16 ounces, twice a day for two weeks, and then once a day thereafter.

A topical cream or ointment is provided that provides for the binding to CB1 and/or CB2 receptors for the soothing of pain, inflammation of smooth muscle, tendons, ligaments, skeletal muscle, endothelial cell, synovial cell, peripheral nerve fibers, reduction of endothelial bruising, promotion of healing of endothelial bruising, and dermatological itch sensation wherein the improvement comprises providing the effect of cannabinoid using plant extracts.

A topical cream or ointment is provided that provides for the binding to CB1 and/or CB2 receptors for the soothing of pain, inflammation of smooth muscle, tendons, ligaments, skeletal muscle, endothelial cell, synovial cell, peripheral nerve fibers, reduction of endothelial bruising, promotion of healing of endothelial bruising, and dermatological itch sensation wherein the improvement comprises providing the effect of cannabinoid using plant extracts.

A topical cream or ointment is provided that provides for the binding to CB1 and/or CB2 receptors for the soothing of pain, inflammation of smooth muscle, tendons, ligaments, skeletal muscle, endothelial cell, synovial cell, peripheral nerve fibers, reduction of endothelial bruising, promotion of healing of endothelial bruising, and dermatological itch sensation wherein the improvement comprises providing the effect of cannabinoid using plant extracts.

A method for inhibiting extension of an ocular axis, wherein the extension of the ocular axis is inhibited by a manner of increasing the volume of choroidal blood flow. The method may include expanding choroidal vessels by using drugs, including locally administering a drug increasing the volume of choroidal blood flow to an eye.